Related Articles
Plasminogen activator inhibitor-1 in kidney pathology (Review)
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure
Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice
Analysis of the inhibition of PAI-1 by metal theaflavin complexes and their degradation products
Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.